Transcriptome sequencing to identify novel prognostic markers and therapeutic targets in acute myeloid leukemia

Principal Investigator: Guy Sauvageau
Theme : Health
Competition : Genomics research in human health - general stream
Status : Completed
Start : Oct. 1, 2010
End: Sept. 30, 2013
Budget : $3,397,008.00



In Canada, acute leukemia remains the leading cause of cancer deaths amongst young adults. Despite significant progress in treating a rare subset of acute myeloid leukemias (AML), most patients diagnosed with this disease will die within a few years of diagnosis. Although chromosome analysis of leukemic cells currently represents the most important tool to establish the prognosis of patients suffering from AML, this tool is proven inefficient in almost 50% of patients.


Researchers involved in this project have developed the necessary research infrastructure (Banque de cellules leucémiques du Québec (BCLQ) at Maisonneuve-Rosemont hospital and IRIC, the expertise (high-throughput sequencing) and advanced analytic tools in bioinformatics to identify novel genetic alterations which will aid in predicting prognosis in AML patients and by developing new markers to allow better treatment for these patients.

 

Co-applicants:

Frédéric Barabé CHUL Research Center
Michel Bouvier Institute for Research in Immunology and Cancer (IRIC)
Josée Hébert Hôpital Maisonneuve-Rosemont
Sebastien Lemieux Institute for Research in Immunology and Cancer (IRIC)
Brian Wilhelm Institute for Research in Immunology and Cancer (IRIC)